2-氨基-4-甲基戊酸甲酯 | 18869-43-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氨基-4-甲基戊酸甲酯
• 英文名称: DL-leucine methyl ester
• 英文别名: leucine methyl ester；methyl leucinate；methyl-2-amino-4-methyl-pentanoate；methyl 2-amino-4-methylpentanoate
• CAS: 18869-43-7
• 化学式: C₇H₁₅NO₂
• mdl: MFCD00044578
• 分子量: 145.202
• InChiKey: QVDXUKJJGUSGLS-UHFFFAOYSA-N

物化性质

• 熔点：
  234-235 °C
• 沸点：
  169.2±13.0 °C(Predicted)
• 密度：
  0.955±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-氨基-4-甲基戊酸甲酯 在 吡啶 、 sodium methylate 作用下， 以 乙醇 、 水 为溶剂， 反应 48.0h， 生成 N-乙酰-L-亮氨酸
  参考文献：
  名称：

  面包酵母的对映体选择性水解-II：正乙酰基氨基酸的酯1

  摘要：

  DN-乙酰基氨基酸酯是通过使用发酵酵母通过其外消旋物的对映体选择性水解而获得的。有证据表明蛋白酶是所涉及的酶。

  DOI：

  10.1016/s0040-4020(01)90011-0
• 作为产物：
  描述：

  methyl 2-((tert-butoxycarbonyl)amino)-4-methylpentanoate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 2-氨基-4-甲基戊酸甲酯
  参考文献：
  名称：

  基于包含两种不同手性单元的手性冠醚对 α-氨基酸衍生物在两种非对映手性固定相上的对映体拆分

  摘要：

  两种非对映异构手性固定相 (CSP) 用于液相色谱拆分各种外消旋 α-氨基甲酯、α-氨基 N,N-二乙基酰胺和 α-氨基 N-丙基酰胺。将 (R)-3,3'-diphenyl-1,1'-binaphtyl 和 (R,R)-酒石酸单元作为手性屏障的 CSP 没有显示出任何手性识别。相反，发现包含 (R)-3,3'-diphenyl-1,1'-binaphtyl 和 (S,S)-酒石酸单元作为手性屏障的 CSP 具有出色的手性识别能力，尤其是对于 α 的两种对映异构体-氨基N-丙基酰胺。在包含 (R)-3,3'-二苯基-1,1'-联萘基和 (S,S)-酒石酸单元的 CSP 上，一些 α-氨基甲酯和 α-氨基 N,N-二乙酰胺也被拆分.

  DOI：

  10.5012/bkcs.2010.31.6.1551
• 作为试剂：
  描述：

  3,6-endomethylene-1,2,3,6-tetrahydrophthalic anhydride 在 N-羟基丁二酰亚胺 、 2-氨基-4-甲基戊酸甲酯 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.25h， 生成 (S)-2-((1R,2S,6R,7S)-3,5-Dioxo-4-aza-tricyclo[5.2.1.0^2,6]dec-8-en-4-yl)-4-methyl-pentanoic acid methyl ester
  参考文献：
  名称：

  Demonstration of endo-cis-(2S,3R)-Bicyclo[2.2.1]hept-5-en-2,3- dicarbonyl Unit as a Reverse-Turn Scaffold and Nucleator of Two-Stranded Parallel β-Sheets:  Design, Synthesis, Crystal Structure, and Self-Assembling Properties of Norborneno Peptide Analogues

  摘要：

  endo-cis-(2S,3R)-Bicyclo[2.2.1]hept-5-en (norbornene) dicarbonyl unit with a built-in U-architecture has been demonstrated to be an excellent reverse-turn molecular scaffold. A large variety of endo-cis-(2S,3R)-norborneno bispeptides containing almost all of the coded amino acids were synthesized and examined for conformational preferences by H-1 NMR, FT-IR, CD, and X-ray crystallographic studies. While FT-IR and H-1 NMR variable-temperature studies ruled out the presence of any significant amount of intramolecular hydrogen bonding in simple bispeptides (3a-h) (except in Aib bispeptide), the CD studies were clearly in favor of a beta-turn type structure. Single-crystal X-ray studies on Aib, Val and Leu containing norborneno bispeptides (3b-d) provided convincing proof for the presence of reverse-turn conformation. While the interstrand C-alpha-C-alpha' distances (5.2-5.7 Angstrom) were well within the range of those for beta-turn structures, no interstrand intramolecular hydrogen bonding was seen in Val and Leu bispeptides; the Aib bispeptide forms a seven-membered hydrogen-bonded ring, thus, showing that the norbornene (2S,3R)-dicarbonyl template assembles peptide chains in reverse-turn conformation by virtue of its built-in U-shaped architecture at these positions, and hydrogen bonding may not be necessary to stabilize the turn structure. The endo-cis-(2S,3R) orientation of bispeptide chains is essential for turn structure as shown by the crystal structure of trans-(2R, 3R) and trans-(2S,3S) derivative of Val bispeptide wherein the two peptide chains move away from each other with the C-alpha-C-alpha' distance increasing to 7.1-8.2 Angstrom. The norbornene 5,6-double bond was hydrogenated to 5,6-dihydro derivative which showed almost the same CD spectrum as its olefinic analogue. Oxidative cleavage [Ru (VIII)] of the 5,6-double bond in norborneno bispeptides, as demonstrated with Leu bispeptide, afforded novel cyclopentanoid peptide analogues. The promise of norbornene unit as a template for nucleating the formation of two-stranded parallel beta-sheets with minimum structural complexity is shown by the preparation of higher members of norborneno bispeptides with the general structure NBE(Pep)(2) [NBE = endo-cis-(2S,3R)-bicyclo[2.2.1]hept-5-en (norbornene) dicarbonyl unit; Pep = peptide strand with two, three, or four (same or different) amino acid residues]. In H-1 NMR, the high (3)J(HN alpha) values (7.0-9.3 Hz) observed for the amide protons (Table 5) coupled with the presence of medium to strong intrastrand sequential ROE connectivities d(alpha N(i,i+1)) spanning the entire three- or four-residue sequence in the peptide strands of 9a-e and 10 and the exhibition of relatively low-temperature coefficients (d delta/dT = -0.2 to -3.4 ppb/K) for amide protons in DMSO-d(6) solvent (Table 4) clearly suggested that hydrogen-bonded beta-sheet conformers dominate the population. FT-IR and CD studies provided further support for parallel beta-sheet structures. A particularly unique feature of the norborneno bispeptides is their strong tendency to self-assemble in the solid state.Thus, while endo-cis-(2S,3R)-Aib bispeptide (3b) forms 16-membered hydrogen bonded centrosymmetric dimers, the half-ester half-acid and the dicarboxylic acid derivatives of 3b self-assemble to form highly ordered hydrogen-bonded molecular ribbons. The Val and Leu cis-(2S, 3R)-bispeptides organize into hydrogen-bonded chains and the trans isomer of Val bispeptide self-assembles into hydrogen-bonded beta-sheet ribbon.

  DOI：

  10.1021/ja980143+

文献信息

• [EN] 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK<br/>[FR] AMIDES HÉTÉROCYCLIQUES À 5 CHAÎNONS ET BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE ROCK
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019014308A1

  公开（公告）日：2019-01-17

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了化合物的结构式（I）：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。
• PEPTIDE TURN MIMETICS
  申请人：Cassidy Peter Joseph

  公开号：US20110040087A1

  公开（公告）日：2011-02-17

  Peptide mimetics of structure X herein which (i) provide a wide range of sidechain functions at all sidechain positions, (ii) can be incorporated in a peptide sequence, (iii) can be readily synthesized and (iv) have a variety of conformations. There is also provided a novel process which can provide valuable intermediates in relation to production of peptide mimetics of structure X which intermediates have a high degree of chemo- and stereo-selectivity. Preferred mimetics include structures I, II, III, IV, V and VI.

  本文中的结构X的肽类拟体具有以下特点：(i) 在所有侧链位置提供广泛的侧链功能，(ii) 可以被纳入肽序列中，(iii) 可以被轻松合成，(iv) 具有多种构象。还提供了一种新的过程，可以提供与结构X的肽类拟体的生产相关的有价值的中间体，这些中间体具有高度的化学和立体选择性。首选的拟体包括结构I、II、III、IV、V和VI。
• Exploring the ability of dihydropyrimidine-5-carboxamide and 5-benzyl-2,4-diaminopyrimidine-based analogues for the selective inhibition of L. major dihydrofolate reductase
  作者：Maria Bibi、Naveeda Akhter Qureshi、Abdul Sadiq、Umar Farooq、Abbas Hassan、Nargis Shaheen、Irfa Asghar、Duaa Umer、Azmat Ullah、Farhan A. Khan、Muhammad Salman、Ahtaram Bibi、Umer Rashid

  DOI：10.1016/j.ejmech.2020.112986

  日期：2021.1

  2,4-diamine, the impact of different amino acids (valine, tryptophan, phenylalanine, and glutamic acid) and two carbon linkers were explored (52-59). The synthesized compounds were assayed against LmDHFR. Compound 59 with the IC50 value of 0.10 μM appeared as potent inhibitors of L. major. Selectivity for parasite DHFR over human DHFR was also determined. Derivatives 55-59 demonstrated excellent selectivity

  为了解决利什曼病，应寻求有效的治疗药物靶标。二氢叶酸还原酶（DHFR）被认为是治疗利什曼病的关键靶标。在当前的研究中，我们感兴趣的是设计和合成针对L. major的针对DHFR的选择性抗叶酸药物。我们专注于基于3,4-二氢嘧啶-2-一和5-（3,5-二甲氧基苄基）嘧啶-2,4-二胺基序的新型抗叶酸药物的开发。对二氢嘧啶（26-30）模板的4-苯环进行了结构活性关系（SAR）研究。对于5-（3,5-二甲氧基苄基）嘧啶-2,4-二胺，研究了不同氨基酸（缬氨酸，色氨酸，苯丙氨酸和谷氨酸）和两个碳连接基的影响（52-59）。针对Lm DHFR测定合成的化合物。化合物59与IC 50 0.10μM的值表现为的强效抑制剂硕大利什曼原虫。还确定了寄生虫DHFR相对于人DHFR的选择性。衍生物55-59对Lm DHFR具有出色的选择性。化合物56（SI = 84.5）和58（SI = 87.5）显示出对Lm
• [EN] C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS<br/>[FR] AMIDES C-28 DE DÉRIVÉS D'ACIDE BÉTULINIQUE MODIFIÉS EN C-3, UTILISÉS COMME INHIBITEURS DE MATURATION DU VIH
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011153319A1

  公开（公告）日：2011-12-08

  Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 and C-28 betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.

  具有药物和生物活性的化合物、其药物组合物及其使用方法。特别是，提供了一种具有独特抗病毒活性的改性C-3和C-28桦木酸衍生物，用作HIV成熟抑制剂。这些化合物可用于治疗HIV和艾滋病。
• Inhibitors of protein isoprenyl transferases
  申请人：University of Pittsburgh

  公开号：US20020193596A1

  公开（公告）日：2002-12-19

  Compounds having the formula 1 or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 —, and (i) heterocyclic-L 2 —; R 2 is selected from (a) 2 (b) —C(O)NH—CH(R 14 )—C(O)OR 15 , (c) 3 (d) —C(O)NH—CH(R 14 )—C(O)NHSO 2 R 16 (e) —C(O)NH—CH(R 14 )-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R 14 )—C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) —L 4 —N(R 5 )—L 5 —, (b) —L 4 —O—L 5 —, (c) —L 4 —S(O) n —L 5 — (d) —L 4 -L 6 —C(W)—N(R 5 )—L 5 —, (e) —L 4 -L 6 —S(O) m —N(R 5 )—L 5 —, (f) —L 4 —N(R 5 )—C(W)—L 7 -L 5 —, (g) —L 4 —N(R 5 )—S(O) p —L 7 —L 5 —, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

  具有以下公式的化合物或其药学上可接受的盐，其中R1为(a)氢，(b)较低的烷基，(c)烯基，(d)烷氧基，(e)硫代烷氧基，(f)卤素，(g)卤代烷基，(h)芳基-L2—，以及(i)杂环-L2—；R2从(a)中选择，(b) -C(O)NH-CH(R14)-C(O)OR15，(c)中选择，(d) -C(O)NH-CH(R14)-C(O)NHSO2R16，(e) -C(O)NH-CH(R14)-四唑基，(f) -C(O)NH-杂环，以及(g) -C(O)NH-CH(R14)-C(O)NR17R18；R3为杂环，芳基，取代或未取代的环烷基；R4为氢，较低烷基，卤代烷基，卤素，芳基，芳基烷基，杂环基，或(杂环)烷基；L1为空缺或从(a) -L4-N(R5)-L5-，(b) -L4-O-L5-，(c) -L4-S(O)n-L5-，(d) -L4-L6-C(W)-N(R5)-L5-，(e) -L4-L6-S(O)m-N(R5)-L5-，(f) -L4-N(R5)-C(W)-L7-L5-，(g) -L4-N(R5)-S(O)p-L7-L5-，(h)可选择取代的烷基，(i)可选择取代的烯基，以及(j)可选择取代的炔基是蛋白异戊二烯转移酶的抑制剂。还公开了蛋白异戊二烯转移酶抑制组合物和抑制蛋白异戊二烯转移酶的方法。